SiameseKitty711 -- I want to reason only one thing
In the past I have posted Pharma companies which make $0 sales , and are in Phase II stage ( highly uncertain) they are valued $3 Billion and above
Here we have a company which makes money and has Ruconest approval + Rifamycin MMX (both in 2014 ) and SAN 300 going into Phase II
how come this is valued at $1.5 Billion ? besides that they have $2 / share cash + Par money which is going pour in..
Patience , any day company is going to release positive news as mentioned in the transcript
Our SAN-300, our monoclonal antibody, which we plan to initially develop for both rheumatoid arthritis and inflammatory bowel disease, we have held a pre-IND meeting with the FDA to discuss a Phase IIa clinical study with a subcutaneous dosage formulation to evaluate safety, the efficacy parameters, and PK/PD and patients with rheumatoid arthritis, and are moving forward to submit an IND in the coming weeks.
I know what you mean. This is a gem and will go way higher. Cash is piling up and pipeline is fruitful. A phase 2 that I am now in is ZLCS. If the market cap is only 100-200 million it is OK to do them if they have a chance for good results. SNTS cash can be used to expand like QCOR and VPHM are doing. Not much to worry about here, buy the dips, some just saying this went up too fast (it made up for 1-2 bad years IMO).
I just had a look at ZLCS up 20% Zalicus completes patient enrollment in two Z160 phase 2 studies
so how about SNTS as posted by UPLATAS when they will submit IND ( investigational new drug ) application and when they will complete the enrollment for Phase II for RA , IBD ??